TVGN

Tevogen Bio Holdings Inc. (TVGN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Tevogen Bio is a clinical-stage specialty immunotherapy company developing off-the-shelf, precision T cell therapies (ExacTcell technology) for infectious diseases and cancers. The company's lead candidate, TVGN 489, has completed a Phase 1 proof-of-concept trial for high-risk COVID-19 patients. The company operates as a single segment and has not yet generated any revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased significantly year-over-year for the nine-month period (from $44.2M to $21.5M). This reduction is primarily driven by a decrease in non-cash stock-based compensation expense (from $33.8M to $13.8M) and lower legal/professional fees.
• Net Loss Volatility: While the GAAP net loss for the nine months ended Sep 30, 2025 ($21.6M) is higher than the prior year ($4.3M), the prior year included a one-time non-cash gain of $48.5M from the change in fair value of convertible promissory notes and $7.5M in merger transaction costs. Excluding these items, the underlying operational burn rate has decreased.
• Liquidity Position: Cash balances declined slightly from $1.28M to $1.04M. However, the company has accessed additional financing, including $3.4M drawn from a Loan Agreement and $3.1M net proceeds from an "at-the-market" sales agreement.

Outlook, Risks, and Management Commentary

• Liquidity Runway: Management believes current cash ($1.0M), combined with proceeds from the Sales Agreement, available capacity under the Loan Agreement ($21M remaining), and a committed $7M grant from KRHP, provides sufficient resources to operate for at least the next 12 months.
• Capital Raising: The company entered a Sales Agreement on July 3, 2025, allowing for the sale of up to $50M of common stock. Between July and September 2025, approximately $3.2M in gross proceeds were raised.
• Nasdaq Compliance Risk: The company received a notification from Nasdaq on September 23, 2025, stating its stock price had been below the $1.00 minimum bid price requirement for 30 consecutive days. The company has 180 days to regain compliance or face potential delisting.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective due to material weaknesses in internal control over financial reporting.
• Development Status: The company does not plan to initiate new clinical trials until additional funding is secured. It continues to rely on grants and debt financing to fund operations.

Investor Verification Checklist

• Nasdaq Delisting Risk: Verify the current stock price and the company's plan to regain compliance with the $1.00 minimum bid price requirement by March 2026.
• Debt Covenants & Related Party Transactions: Review the terms of the $36M Loan Agreement with The Patel Family, including the interest payable in stock and the contingent purchase options (PIPE) that could trigger significant dilution.
• Internal Control Weaknesses: Assess the specific material weaknesses in financial reporting and the remediation plan to ensure future financial data reliability.
• Preferred Stock Liquidation Preferences: Analyze the liquidation priority of Series A and Series C Preferred Stock, which rank senior to common stock and carry cumulative dividends.
• Grant Funding Reliance: Confirm the status of the $7M committed grant from KRHP and the conditions attached to its disbursement.